Sign in

You're signed outSign in or to get full access.

FB

Fortress Biotech, Inc. (FBIO)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 net revenue reached $16.41M, up 10.2% YoY; product revenue was $15.01M, driven by Journey Medical’s dermatology portfolio including the Emrosi launch .
  • Diluted EPS swung to a profit at $0.45 versus $(0.73) in Q2 2024, largely due to a $27.13M gain from deconsolidation of a subsidiary; SG&A rose sharply to $38.76M, offset by lower R&D expenses .
  • Fortress closed the sale of Checkpoint Therapeutics to Sun Pharma, receiving ~$28M cash at closing, eligibility for up to $4.8M under a CVR, and a 2.5% royalty on future UNLOXCYT sales—adding monetization and balance sheet strength .
  • Upcoming regulatory catalyst: CUTX-101 NDA under priority review with a PDUFA goal date of September 30, 2025; Cyprium retains 100% ownership of any Priority Review Voucher upon approval .

What Went Well and What Went Wrong

What Went Well

  • Monetization event: Checkpoint acquisition closed; Fortress received ~$28M at closing and retains a 2.5% royalty and potential CVR up to $4.8M—management called it “another successful milestone” that strengthens the balance sheet .
  • Positive EPS surprise: Q2 diluted EPS was $0.45 vs $(0.73) YoY, aided by a $27.13M deconsolidation gain and lower R&D spend; management highlighted “key milestones” underscoring portfolio strength .
  • Emrosi commercialization momentum: full launch began April 7; payer coverage expanded to >100M commercial lives by July (65% of U.S. commercial lives), supporting rosacea market uptake .

What Went Wrong

  • Operating cost pressure: SG&A increased to $38.76M vs $20.82M YoY, reflecting higher corporate and commercial expenses despite revenue growth .
  • Clinical setback at partner level: AstraZeneca’s anselamimab (formerly CAEL‑101) failed the primary endpoint in Phase III CARES for AL amyloidosis (with some subgroup benefit), adding uncertainty to that program’s trajectory .
  • Underlying operating losses persist: loss from operations was $(36.47)M despite top-line growth; operating profitability remains challenged absent non-operational gains .

Financial Results

Consolidated P&L snapshot (oldest → newest)

MetricQ2 2024Q1 2025Q2 2025
Net Revenue ($USD)$14.90M N/A$16.41M
Product Revenue, net ($USD)$14.86M $13.14M $15.01M
Research & Development ($USD)$12.67M $3.94M $8.13M
Selling, General & Administrative ($USD)$20.82M $25.66M $38.76M
Net Income (Loss) to Common ($USD)$(13.34)M $(12.72)M $13.36M
Diluted EPS ($USD)$(0.73) $(0.48) $0.45

Revenue components (Q2 2025)

ComponentAmount ($USD)
Product Revenue, net$15.01M
Revenue – Related Party$0.00M
Other Revenue$1.40M
Net Revenue$16.41M

Margins (GAAP; S&P Global values*)

MetricQ1 2025Q2 2025
EBIT Margin %-169.85%*-222.22%*
EBITDA Margin %-160.79%*-215.18%*
Net Income Margin %-80.55%*94.35%*
Values retrieved from S&P Global.

Balance sheet highlights

MetricQ2 2025
Cash and Cash Equivalents ($USD)$74.39M
Total Assets ($USD)$159.90M
Total Liabilities ($USD)$122.51M
Total Stockholders’ Equity ($USD)$37.38M

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue/EPS/OpExFY/Q3 2025None providedNone providedMaintained (no guidance)
CUTX-101 NDA (Menkes)PDUFAPriority Review accepted; PDUFA 9/30/2025Same; Cyprium retains any PRVMaintained
UNLOXCYT (cosibelimab-ipdl)Royalty/MonetizationPending Sun Pharma dealDeal closed; royalty 2.5% + CVR up to $4.8MRaised visibility (closed)

Earnings Call Themes & Trends

Note: No Q2 2025 earnings call transcript was available; themes below reflect press releases and 8‑K disclosures.

TopicPrevious Mentions (Q4 2024 and Q1 2025)Current Period (Q2 2025)Trend
MonetizationSun Pharma–Checkpoint agreement; ~$28M expected, 2.5% royalty Deal closed; ~$28M received, CVR up to $4.8M, 2.5% royalty Positive completion
RegulatoryEmrosi and UNLOXCYT FDA approvals; CUTX‑101 NDA accepted, PDUFA set CUTX‑101 Priority Review reaffirmed; PRV may be issued on approval Steady, approaching catalyst
CommercializationEmrosi launch initiated; Journey Q1 net product revenue $13.1M Emrosi payer coverage expanded to >100M lives; Journey Q2 net product revenue $15.0M Improving access and revenue
R&D ExecutionTriplex Phase 2 dosing initiated; Emrosi Phase 3 results published Mustang MB‑101 Orphan Drug Designation; MB‑101/MB‑108 combo strategy Advancing programs
Partnerships/AIPartex collaboration to evaluate compounds with AI Not specifically updatedNeutral
External Program Risk—Anselamimab Phase III primary endpoint miss (AstraZeneca) Mixed (subgroup signal)

Management Commentary

  • “We achieved several key milestones in the second quarter that underscore the strength of Fortress’s diversified business model… delivering approximately $28 million upfront, plus the potential for an additional contingent value right (CVR) payment and ongoing royalties on future sales of UNLOXCYT™” — Lindsay A. Rosenwald, M.D., Chairman, President & CEO .
  • “We also look forward to the PDUFA goal date for CUTX-101… and the potential Priority Review Voucher which may be issued upon approval.” — Lindsay A. Rosenwald, M.D. .
  • “Journey Medical continues to execute well, with the launch of Emrosi™ and commercial uptake, including expanded payer coverage now reaching 65% of U.S. commercial lives.” — Lindsay A. Rosenwald, M.D. .

Q&A Highlights

No Q2 2025 earnings call transcript was available; therefore, Q&A themes and guidance clarifications cannot be assessed for this quarter [ListDocuments results showing none].

Estimates Context

  • Revenue beat: Q2 2025 reported net revenue $16.41M vs S&P Global consensus $14.53M — a top-line beat driven by Journey’s $15.01M product contribution and additional other revenue .
  • EPS surprise: Reported diluted EPS $0.45 vs S&P Global consensus Primary EPS of $(0.36); the upside stems primarily from a $27.13M gain from deconsolidation, partly offset by higher SG&A .
    Note: S&P Global “Primary EPS” may differ from reported diluted EPS definitions; comparisons are directional and anchored to consensus.
MetricQ2 2025 Consensus EstimateQ2 2025 Reported
Revenue ($USD)$14.53M*$16.41M
EPS ($USD)$(0.36)*$0.45
Values retrieved from S&P Global.

Key Takeaways for Investors

  • Strong monetization execution and upcoming regulatory catalyst create a favorable near-term setup (Checkpoint cash + UNLOXCYT royalty + CUTX‑101 PDUFA 9/30) .
  • The EPS beat was driven by non-operational gains (deconsolidation); underlying operations remain loss-making with elevated SG&A—watch cost discipline and operating leverage trajectory .
  • Emrosi’s national payer access (>100M lives) and Journey’s $15.0M Q2 product revenue underpin dermatology growth; monitor sequential trends and formulary expansion .
  • Balance sheet improved with Q2 cash at $74.39M and equity turning positive; liquidity supports pipeline and BD flexibility near catalysts .
  • External program risk exists (anselamimab Phase III miss), but portfolio diversification and selective royalty/equity positions mitigate single-asset exposure .
  • Near-term trading implications: potential catalyst run-up into CUTX‑101 PDUFA; assess risk-reward given EPS normalization once non-recurring gains fade .
  • Medium-term thesis: value creation via royalties (UNLOXCYT), dermatology cash flows (Journey), and milestone-driven approvals (CUTX‑101), tempered by cost structure and execution risks .